Vanworld Pharmaceutical (Rugao) Company Limited is subordinate to Hong Kong Hongwei Pharmaceutical Group. It is a biomedical high-tech enterprise with significant profit potential, dominated by the demand of the global pharmaceutical market and based on innovative research. It is committed to the development and research of original new drugs with independent intellectual property rights.
"Extracts from rabbit skin inflamed by vaccine virus for injection" is a therapeutic biological product produced by Vanworld Pharmaceutical (Rugao) Company Limited, with the trade name of "lizaishi". . Because of its outstanding efficacy and safety, this product is popular in the medical community.
The company obtained the national drug GMP certification in December 2002. It boasts a modern factory building covering an area of 10,840 square meters, equipped with three workshops for active pharmaceutical ingredients, aqueous injections, and tablets, with an annual production capacity of 50 million units。
The group has invested heavily in pharmaceutical research. In addition to continuously strengthening its independent research and development capabilities, it has successfully completed multiple research and development projects through cooperation with top research institutions such as the Chinese Academy of Sciences, the University of Cambridge in the UK, the Academia Sinica in Taiwan, Capital Medical University in China, and the Zhejiang Academy of Medical Sciences, thereby realizing the group's potential scientific and commercial value.
The company is committed to the research and promotion of new drugs. Among them, "Lizaisi" (Vaccinia Virus Inflammation Rabbit Skin Extract Injection) is a product with independent intellectual property rights, produced exclusively in China, and has obtained two patents for manufacturing process and raw materials.
Lyrica has rapidly become a recommended drug in the treatment of various neuralgias, serving as a medication for clinicians to treat intractable low back pain, residual neurological symptoms after spinal surgery, postherpetic neuralgia, trigeminal neuralgia, and more.
The company emphasizes the authenticity, accuracy, integrity, timeliness, and legality of clinical trial data, and actively participates in clinical trials to ensure the safety and effectiveness of drugs.
Research and Development Innovation: Investing in cutting-edge pharmaceutical technologies, pursuing continuous technological innovation and improvement, solving various problems in the field of neuropathic pain, and becoming a leader in the pharmaceutical industry.
Customer first: Guided by customer needs, we strive to improve the quality of our products and services through continuous quality improvement.
Sustainable development: Emphasize long-term development, balance the economy, society, and environment, strive to achieve the unity of economic, social, and environmental benefits, promote sustainable development of enterprises, and commit to environmental protection and social contribution.
苏ICP备 19025xxx号-1 苏公网安备3101070200xxxx号
Copyright © 2024 Vanworld Pharmaceutical (Rugao) Company Limited All Rights Reserved
Scan code follow us